URGENT MEDICINE RECALL

RC-2020-RN-01478-1

TENOFOVIR DISOPROXIL EMTRICITABINE MYLAN 300/200 (AUST R 265834)

ALL BATCHES WITHIN EXPIRY

Alphapharm Pty Ltd, following consultation with the Therapeutic Goods Administration (TGA), is initiating a consumer level recall of all batches within expiry of TENOFOVIR DISOPROXIL EMTRICITABINE MYLAN 300/200 tablets.

The consumer level recall is being requested as a precautionary measure due to the potential for broken and/or split tablets. In the event a broken /split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety.

Tenofovir Disoproxil Emtricitabine Mylan 300/200 is indicated for:

- The treatment of HIV-infected adults over the age of 18 years, in combination with other antiretroviral agents.
- In combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Patients that have been prescribed TENOFOVIR DISOPROXIL EMTRICITABINE MYLAN 300/200 should consult their treating physician for individual advice.

Patients that have any units of the unexpired batches should return them to their pharmacist for a refund.

Should you require any further information please contact

1 800 274 276.

Thank you in advance for your support in this matter.